SCOTUS declines to take up 'skinny' label generic drug case, raising questions about future carve outs
The Supreme Court decided on Monday to not take up a controversial court decision that may have ripple effects across the generic drug industry. The industry has long been allowed to bring generic drugs to market by carving out the label to avoid certain indications that are still under patent protection. Now that practice may be in jeopardy.
So-called “skinny” label generic drugs haven’t been controversial until more recently, when a court battle between Teva and GlaxoSmithKline over GSK’s beta-blocker Coreg (carvedilol), which Teva launched a generic of in 2007, ignited questions around the future of such carve-outs.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters